Skip to main content
RadioMedix, Areva to launch early-stage trial of neuroendocrine tumor drug
1/12/2018

An early-stage study was launched by RadioMedix and Areva Med to evaluate their treatment, AlphaMedix, for safety, biodistribution and preliminary effectiveness in adult patients with somatostatin receptor-positive neuroendocrine tumors.

Full Story: